User:Mr. Ibrahem/Erdafitinib

Mr. Ibrahem/Erdafitinib
Clinical data
Trade names	Balversa
Other names	JNJ-42756493
AHFS/Drugs.com	Monograph
MedlinePlus	a619031
License data	US DailyMed: Erdafitinib; US FDA: Balversa;
Routes of; administration	By mouth
Drug class	Fibroblast growth factor receptor (FGFR) blocker
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name N'-(3,5-dimethoxyphenyl)-N'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine;
Chemical and physical data
Formula	C25H30N6O2
Molar mass	446.555 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC;
	InChI InChI=1S/C25H30N6O2/c1-17(2)26-8-9-31(20-10-21(32-4)13-22(11-20)33-5)19-6-7-23-24(12-19)29-25(15-27-23)18-14-28-30(3)16-18/h6-7,10-17,26H,8-9H2,1-5H3; Key:OLAHOMJCDNXHFI-UHFFFAOYSA-N;

Erdafitinib, sold under the brand name Balversa, is a medication used to treat urothelial cancer.^[2] Specifically it is used for cases which have suitable FGFR-2 or 3 mutations.^[2] It is taken by mouth.^[2]

Common side effects include high phosphate, mouth inflammation, tiredness, kidney problems, diarrhea, liver problems, change in taste, low magnesium, hair loss, high calcium, and muscle pain.^[2] Other side effects may include infertility and vision problems.^[2] Use in pregnancy may harm the baby.^[2] It is a tyrosine kinase inhibitor, specifically a fibroblast growth factor receptor (FGFR) blocker.^[1]^[2]

Erdafitinib was approved for medical use in the United States in 2019.^[2] It is not approved for use in the United Kingdom or Europe as of 2021.^[1] In the United States 4 weeks of treatment costs about 21,500 USD as of 2021.^[3]

References[edit]

^ ^a ^b ^c "Erdafitinib". SPS - Specialist Pharmacy Service. 5 October 2018. Archived from the original on 11 January 2022. Retrieved 15 December 2021.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Erdafitinib Monograph for Professionals". Drugs.com. Archived from the original on 3 January 2022. Retrieved 15 December 2021.
^ "Erdafitinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 15 December 2021.

[SP2021-1] "Erdafitinib". SPS - Specialist Pharmacy Service. 5 October 2018. Archived from the original on 11 January 2022. Retrieved 15 December 2021.

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Erdafitinib Monograph for Professionals". Drugs.com. Archived from the original on 3 January 2022. Retrieved 15 December 2021.

[3] "Erdafitinib Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 15 December 2021.

[1]

[2]

[3]